Compare Becton Dickinson and Co (BDX) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Lockheed Martin Corporation — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Lockheed Martin Corporation trades at $598.13 (market cap $139.20B). The key difference: Lockheed Martin Corporation is far larger — about 2.8× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | LMT | |
|---|---|---|
Market Cap | $48.93B | $139.20B |
Sector | Health | Industrials |
52-Week High | $185.39 | $676.70 |
52-Week Low | $138.62 | $426.26 |
Enterprise Value | $65.03B | $155.95B |
Dividend Yield | 2.34% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Lockheed Martin (LMT) trades at $587.95, up 0.9% with bullish technical signals and strong institutional support. The company reported mixed Q2 2026 earnings with a beat on EPS ($7.94 vs. $7.22 expected) but maintains a record $230B backlog. Valuation metrics show a P/E of 21.68 and ROE of 89.16%, though recent quarters saw earnings misses. Technical indicators suggest bullish momentum with key resistance at $592.
Outlook remains positive driven by defense contract wins and production expansion, but risks include execution on massive backlog and debt levels. Analyst consensus is bullish with $608 price target representing 3.4% upside. The stock offers stability through dividends ($3.45 quarterly) amid geopolitical demand for defense systems.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
